Enanta Pharmaceuticals, Inc.
ENTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -17.4% | 22.7% | -12% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -107.6% | -84.1% | -140.9% | -117.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -123.6% | -99.7% | -151.7% | -131.4% |
| EPS Diluted | -0.87 | -0.85 | -1.06 | -1.05 |
| % Growth | -2.4% | 19.8% | -1% | – |
| Operating Cash Flow | – | $0 | -$0 | -$0 |
| Capital Expenditures | – | -$0 | -$0 | -$0 |
| Free Cash Flow | – | $0 | -$0 | -$0 |